> Back to EJC

Recent editions

  • March 2015
    Christopher Wild on the exposome, a measure of environmental exposure.
  • February 2015
    Mathematicians are developing a blood flow model for metastasis.
  • January 2015
    René Bernards on discovering effective drug combinations.
  • December 2014
    Research on the high rate of burnout among young oncologists.
  • November 2014
    Carl June on the efficacy of CAR-T cells in treating leukaemia.
  • October 2014
    News from ESMO 2014 with Solange Peters and Alexander Eggermont.
  • September 2014
    Discussing how healthcare systems can meet the needs of cancer survivors.
  • July/August 2014
    Sophie Postel-Vinay on new recommendations for phase 1 trials.
  • June 2014
    Hans Clevers on important research into stem cells in normal gut tissue.
  • May 2014
    Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
  • April 2014
    Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
  • March 2014
    The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
  • February 2014
    Charles Swanton on a study that maps genetic changes in cancers over time.

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – October 2013

Loading EJC News Focus video

'New ways of learning are needed' as personalised medicine enters routine practice

Prospective observational registries, which record every clinical encounter with every patient, are going to be the way to continue progress in our understanding of cancer, according to Richard L Schilsky, Chief Medical Officer of the American Society of Clinical Oncology (ASCO).

Genetic characterisation has led to cancers which were traditionally considered common becoming instead a collection of rare diseases. It means that there are now too many cancers, too many drugs in development and not enough patients, time or money to study everything by doing clinical trials, he says.

In this month's EJC News Focus, Schilsky tells Helen Saul that as personalised medicine enters the clinic, changes are needed – and are happening – in research, development and the regulation of new cancer drugs.